Page results
-
This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.
-
The Secretary of State for Health and Social Care, The Rt. Hon. Sajid Javid MP visited the National Hospital for Neurology and Neurosurgery (NHNN), earlier this week (Wednesday 4 May 2022).
-
Doctors at UCLH and University College London (UCL) have developed a digital decision-making aid, MENO.pause, to help clinicians manage menopause symptoms in the best way for individual patients’ health conditions.
-
Robot-assisted surgery used to perform bladder cancer removal and reconstruction enables patients to recover far more quickly and spend significantly less time in hospital, concludes a trial led by UCLH, UCL and the University of Sheffield.
-
Matthew Fielden and Lillyanne Tran volunteer in the cognitive disorders outpatients’ clinic at the National Hospital for Neurology and Neurosurgery.
-
Advice on preventing the spread of flu and other respiratory viruses, to keep UCLH patients safe.
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
This page tells you about the procedure known as varicocele (pronounced VARI-CO-SEAL) embolisation.
File results
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment